8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 1, 2026·SEC
Material company update
Apr 24, 2026·SEC
PDS Biotechnology Corporation(PDSB)Earnings, Financials & Key Ratios
PDSB•NASDAQ
$0.89
Price updated Jun 27, 2026
AboutPDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.Show more
- Revenue$0
- EBITDA-$32M+13.1%
- Net Income-$34M+8.3%
- EPS (Diluted)-0.74+28.2%
- ROE-244.16%-46.5%
PDSB Price & Volume
PDS Biotechnology Corporation (PDSB) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Capital Reserves
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Gap
"PDS Biotechnology remains in a high-risk clinical development phase, characterized by a total absence of commercial revenue and persistent quarterly operating losses, such as the $6.5M deficit reported in 2026Q1. The company's reliance on external financing to fund its Versamune platform has led to significant equity erosion, with retained earnings reaching a $224.0M deficit. Investors should monitor the firm's liquidity inflection point, as the current $21.7M cash balance may be insufficient to sustain operations beyond the next 12 to 18 months without further dilutive capital raises."
Verdict Logic
the company's precarious financial position is highlighted by a current ratio that has declined to 2.26 in 2026Q1, signaling limited liquidity to support ongoing clinical trials.
PDSB Growth Metrics
PDS Biotechnology Corporation (PDSB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM6.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM29.47%
Return on Capital
10 Years-73.33%
5 Years-82.65%
3 Years-100.79%
Last Year-128.01%
PDSB Recent Earnings
PDS Biotechnology Corporation (PDSB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.13+13.3%
$0.15
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.14+30.0%
$0.20
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.19+9.5%
$0.21
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.21+12.5%
$0.24
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.13vs $0.15+13.3% | — |
| Q2 2026 | Mar 30, 2026 | $0.14vs $0.20+30.0% | — |
| Q4 2025 | Nov 13, 2025 | $0.19vs $0.21+9.5% | — |
| Q3 2025 | Aug 13, 2025 | $0.21vs $0.24+12.5% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for PDS Biotechnology Corporation (PDSB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.89 | $49.59M | -1.20 | — | — | -244.16% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $4.25 | $1.52B | -3.90 | 60.6% | -123.9% | -50.17% | — | |
| $8.88 | $1.46B | 3.50 | 64.69% | -14.73% | — | — | |
| $1.50 | $507.78M | -6.52 | 8.83% | -1605.22% | -127987.5% | — |
Compare PDSB vs Peers
PDS Biotechnology Corporation (PDSB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PDSB SEC Filings & Documents
PDS Biotechnology Corporation (PDSB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PDSB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PDSB Frequently Asked Questions
PDS Biotechnology Corporation (PDSB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PDSB profitable?
PDS Biotechnology Corporation (PDSB) reported a net loss of $33.4M for fiscal year 2025.
Dividend & Returns
What is PDSB's return on equity?
PDS Biotechnology Corporation (PDSB) has a return on equity (ROE) of -244.2%. Negative ROE indicates the company is unprofitable.
What is PDS Biotechnology Corporation's free cash flow?
PDS Biotechnology Corporation (PDSB) had negative free cash flow of $4.39B in fiscal year 2025, likely due to heavy capital investments.